Validation of co-Symptom Screening in Pediatrics Tool: a novel dyadic approach to symptom screening in pediatric patients receiving cancer treatment

• Published in: JNCI : Journal of the National Cancer Institute Vol. 116; no. 1; pp. 160 - 166
• Main Authors: Tomlinson, Deborah, Dupuis, L Lee, Dix, David, Crellin-Parsons, Nicole, Cook, Sadie, Kulkarni, Ketan, Schechter, Tal, Tomlinson, George A, Sung, Lillian
• Format: Journal Article
• Language: English
• Published: United States 10.01.2024
• Subjects: Adolescent; Child; Child, Preschool; Early Detection of Cancer; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Neoplasms - diagnosis; Neoplasms - therapy; Psychometrics; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Symptom Assessment
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/djad181

Co-Symptom Screening in Pediatrics Tool (co-SSPedi) is a dyadic (child-guardian) approach to symptom assessment. Objectives were to evaluate the reliability and validity of co-SSPedi for pediatric patients receiving cancer treatments. This multicenter study included dyads of patients aged 4-18 years of age with cancer or undergoing hematopoietic cell transplant and their guardians. Two groups were enrolled. The more symptomatic group included those receiving active treatment for cancer or undergoing hematopoietic cell transplant where patients were in hospital or clinic for 4 consecutive days. The less symptomatic group included those receiving maintenance therapy for acute lymphoblastic leukemia or who had completed cancer treatments. At baseline, all dyads completed co-SSPedi, and guardians completed measures of mucositis, nausea, pain, quality of life, and overall symptoms. In the more symptomatic group, dyads completed co-SSPedi and a global symptom change scale on day 4. There were 501 dyads included: 301 in the more symptomatic group and 200 in the less symptomatic group. Median time to complete co-SSPedi was less than 3 minutes in both groups. Test-retest reliability intraclass correlation coefficient was 0.85 (95% confidence interval [CI] = 0.77 to 0.90). For internal consistency, total co-SSPedi Cronbach alpha was 0.81 (95% CI = 0.78 to 0.83). For known groups validation, mean difference in total co-SSPedi scores between the more symptomatic and less symptomatic groups was 7.8 (95% CI = 6.7 to 8.8; P < .0001). For convergent validation and responsiveness, all hypothesized relationships were demonstrated. Co-SSPedi is a novel approach to dyadic symptom assessment that is reliable, valid, and responsive in pediatric patients aged 4-18 years.